Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 6.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 12,072 shares of the biopharmaceutical company’s stock after purchasing an additional 780 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Alnylam Pharmaceuticals were worth $3,320,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Los Angeles Capital Management LLC increased its holdings in Alnylam Pharmaceuticals by 11,433.4% during the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after purchasing an additional 135,829 shares during the period. AQR Capital Management LLC raised its holdings in Alnylam Pharmaceuticals by 92.5% in the second quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company’s stock valued at $65,862,000 after acquiring an additional 130,482 shares in the last quarter. Deerfield Management Company L.P. Series C purchased a new position in Alnylam Pharmaceuticals in the second quarter worth approximately $29,111,000. Avoro Capital Advisors LLC grew its holdings in Alnylam Pharmaceuticals by 33.3% during the 2nd quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock worth $97,200,000 after acquiring an additional 100,000 shares in the last quarter. Finally, Telemark Asset Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $27,503,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

ALNY has been the subject of a number of analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. JPMorgan Chase & Co. upped their price objective on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a research report on Monday, August 26th. Scotiabank raised their target price on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a research report on Friday, November 1st. Canaccord Genuity Group increased their price target on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Finally, Piper Sandler reissued an “overweight” rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $298.09.

Insider Buying and Selling

In related news, EVP Tolga Tanguler sold 1,469 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the transaction, the executive vice president now directly owns 13,191 shares of the company’s stock, valued at $3,310,677.18. This trade represents a 10.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Yvonne Greenstreet sold 5,219 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the transaction, the chief executive officer now directly owns 78,880 shares of the company’s stock, valued at $19,797,302.40. This trade represents a 6.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 8,370 shares of company stock valued at $2,100,703 over the last quarter. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 0.2 %

Shares of NASDAQ:ALNY opened at $253.74 on Thursday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The firm’s 50-day simple moving average is $272.32 and its 200-day simple moving average is $240.10. The company has a market cap of $32.73 billion, a price-to-earnings ratio of -96.85 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. The company’s quarterly revenue was down 33.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.15 earnings per share. As a group, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.